Yes, Luxbio.net provides robust support for the analysis of alternative splicing events, offering a comprehensive suite of bioinformatics tools and databases specifically designed for this complex task. The platform is engineered to handle the entire workflow, from raw RNA sequencing (RNA-seq) data processing to the visualization and biological interpretation of different splicing isoforms. This capability is critical because alternative splicing is a fundamental mechanism for increasing proteomic diversity, and its dysregulation is implicated in numerous diseases, including cancer and neurological disorders. The platform’s strength lies not in a single tool, but in an integrated ecosystem that addresses the multifaceted challenges of splicing analysis.
Core Analytical Framework and Supported Splicing Types
The analytical engine at the core of luxbio.net is built upon established, peer-reviewed algorithms, ensuring accuracy and reliability. The platform can detect and quantify a wide spectrum of alternative splicing events with high precision. Users can typically analyze millions of reads from standard Illumina RNA-seq experiments, with the system capable of scaling to process hundreds of samples in a batch. The primary types of splicing events supported include:
- Exon Skipping (Cassette Exon): The most common type in mammals, where an exon is either included or skipped in the final mRNA transcript.
- Mutually Exclusive Exons: Where one of two exons is included, but never both.
- Alternative 5′ Splice Sites: Variation in the donor site at the 5′ end of an intron, leading to exons with different start points.
- Alternative 3′ Splice Sites: Variation in the acceptor site at the 3′ end of an intron, leading to exons with different end points.
- Intron Retention: Where an intron is not spliced out and remains in the mature mRNA.
The platform quantifies these events using metrics like Percent Spliced In (PSI or Ψ), which represents the fraction of mRNAs from a gene that include a particular exon or splicing event. A PSI value of 1.0 means the exon is always included, while 0.0 means it is always skipped. Detecting a statistically significant change in PSI (e.g., ΔPSI > 0.1 or 0.2) between experimental conditions (like disease vs. control) is a primary goal of the analysis.
| Splicing Event Type | Detection Method Used | Key Quantification Metric | Typical Data Input Requirement |
|---|---|---|---|
| Exon Skipping | Exon-centric counting (e.g., DEXSeq-based) | PSI (Percent Spliced In) | Stranded, paired-end RNA-seq (≥ 40M reads) |
| Intron Retention | Intron-read coverage analysis | Intron Retention Ratio (IRR) | Non-strand-specific OK, but stranded preferred |
| Alternative 5’/3′ Sites | Junction-spanning read analysis | Junction Read Counts, PSI | High depth at splice junctions is critical |
The Step-by-Step Analytical Workflow
The process on the platform is streamlined into a logical workflow, making sophisticated analysis accessible to users without extensive command-line bioinformatics expertise.
Step 1: Data Upload and Quality Control. The process begins with uploading raw FASTQ files or aligned BAM files. The platform performs automated quality checks, providing users with a report that includes metrics like read quality scores, adapter contamination, and ribosomal RNA content. This step is crucial, as poor-quality data can lead to a high false-positive rate in splicing detection. For instance, the platform might flag a sample if more than 20% of its reads have a Phred quality score below 20, prompting the user to consider re-sequencing or more aggressive trimming.
Step 2: Alignment and Splice Junction Detection. The uploaded reads are aligned to a reference genome (e.g., GRCh38 for human) using a splice-aware aligner like STAR or HISAT2, which are integrated into the platform’s backend. These aligners are specifically tuned to map reads that cross exon-exon junctions, which is the primary evidence for splicing events. The output includes a BAM file of aligned reads and a file detailing all detected splice junctions. A typical human RNA-seq sample might reveal between 150,000 and 300,000 unique splice junctions.
Step 3: Event Identification and Quantification. This is the core analytical step. The platform uses software such as rMATS, SUPPA2, or LeafCutter to systematically scan the aligned data, catalog all potential splicing events based on the junction reads and exon/intron coverage, and calculate their abundance (like PSI) for each sample. For a project with 10 samples per group, this step might identify and quantify over 50,000 potential splicing events across the genome.
Step 4: Differential Splicing Analysis. The platform then performs statistical testing to compare PSI values between user-defined groups (e.g., tumor vs. normal). It accounts for biological variability within groups to calculate a false discovery rate (FDR) or p-value for each event. The output is a list of significantly differentially spliced events, often filtered by a user-adjustable FDR cutoff (e.g., FDR < 0.05) and a minimum ΔPSI (e.g., |ΔPSI| > 0.1).
Visualization and Functional Interpretation
Raw data tables of splicing events are of limited use without intuitive visualization. The platform excels here by integrating genome browser views, such as a customized implementation of the UCSC Genome Browser or IGV. Users can select a significant event and instantly see a visualization like a sashimi plot, which displays the read coverage and the arcs of junction reads, providing immediate, visual confirmation of the alternative splicing. For example, a sashimi plot for an exon skipping event would clearly show a strong “arc” of reads skipping over the exon in the disease condition, compared to a solid coverage of the exon in the control.
Beyond visualization, the platform connects splicing events to biological meaning. It automatically annotates events with gene names, functional domains (e.g., if the skipped exon encodes a kinase domain), and links to public databases like Ensembl and UniProt. Furthermore, it supports gene set enrichment analysis (GSEA) on lists of genes undergoing significant differential splicing. This can reveal, for instance, that genes involved in “apoptotic signaling pathways” are particularly enriched for alternative splicing in a specific cancer dataset, providing a crucial hypothesis for further experimental validation.
Integration with Other Omics Data and Customization
A powerful feature is the ability to integrate splicing data with other analyses. Users can correlate splicing changes (ΔPSI) with gene expression changes (log2 fold-change) from the same RNA-seq experiment to see if a gene is both differentially expressed and alternatively spliced. The platform also allows for the integration of external data, such as CLIP-seq data for RNA-binding proteins (RBPs). By overlaying RBP binding sites, a user can investigate if a specific splicing change might be driven by the dysregulation of an RBP like SRSF1 or HNRNPC, adding a layer of mechanistic insight.
The system is also highly customizable. Advanced users can adjust key parameters, such as the minimum number of junction-spanning reads required to call an event, the statistical models for differential testing, and the thresholds for significance. This flexibility ensures that both discovery-based research with relaxed thresholds and stringent, validation-focused analyses can be performed effectively.
In essence, the platform’s support for alternative splicing analysis is not a single feature but a deeply integrated, end-to-end solution. It handles the computational heavy lifting of data processing and statistical testing while providing the visualization and interpretation tools necessary to transform raw sequencing data into meaningful biological discoveries. This makes it an invaluable resource for researchers in genomics, molecular biology, and drug discovery who are investigating the role of isoform diversity in health and disease.